Next-Generation Vaccines – From Pandemic Response to Future Preparedness
The COVID-19 pandemic fundamentally changed the way the world views vaccines, public health preparedness, biotechnology innovation, and scientific collaboration. Vaccines are no longer seen merely as preventive tools for infectious diseases; they are now becoming strategic platforms capable of addressing future pandemics, cancer, antimicrobial resistance, and emerging global health threats.
This session explores how next-generation vaccine technologies are redefining healthcare preparedness and transforming the future of disease prevention. As the world moves from reactive responses toward predictive and proactive public health systems, vaccine innovation is becoming central to global health security.
The session features Dr. Vinay Nandicoori, Director of the CSIR-Centre for Cellular and Molecular Biology, one of India’s leading molecular biologists and scientific leaders. Dr. Nandicoori has contributed extensively to research in molecular microbiology, infectious diseases, and host-pathogen interactions. Under his leadership, CCMB continues to play a critical role in genomics, translational biology, infectious disease research, and national scientific innovation initiatives.
The discussion will examine how lessons learned from COVID-19 have accelerated vaccine development platforms including mRNA technologies, viral vectors, recombinant proteins, AI-assisted vaccine discovery, and genomic surveillance systems. Emerging technologies are enabling faster identification of pathogens, shorter development timelines, improved efficacy, and greater adaptability against evolving variants.
A key theme of the session will be preparedness. Future pandemics are considered inevitable by many public health experts. The question is not whether another global health crisis will emerge, but whether healthcare systems, governments, researchers, and industries will be prepared to respond rapidly and effectively.
The session will also explore India’s growing role in global vaccine leadership. Hyderabad remains one of the world’s most significant vaccine manufacturing and biotechnology hubs, contributing substantially to global immunization programs. With Genome Valley, leading vaccine manufacturers, biotechnology companies, and research institutions located within the ecosystem, the city has become a critical center for vaccine innovation and production.
Attendees will gain insights into how scientific research, biotechnology, genomics, artificial intelligence, and global collaboration are converging to build more resilient public health systems. The session will highlight opportunities for India to move beyond manufacturing leadership and become a major contributor to vaccine discovery, translational science, and global health innovation.
For healthcare leaders, researchers, policymakers, biotechnology companies, and public health professionals, this discussion offers a strategic perspective on the future of vaccines and their role in protecting societies against emerging health challenges.
